Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | DHODH | Q02127 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291419 | 0.92 | PDE5A (0.69) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL290089 | 0.89 | PDE5A (0.76) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL2680309 | 0.89 | PDE5A (0.76) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29831949 | 0.89 | PDE5A (0.76) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL291321 | 0.89 | PDE5A (0.76) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29831789 | 0.88 | PDE5A (0.79) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL291110 | 0.88 | PDE5A (0.79) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL290627 | 0.87 | PDE5A (0.64) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL291286 | 0.87 | PDE5A (0.77) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL292060 | 0.87 | PDE5A (0.77) | PDE5AMAPTKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640395-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012064667-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-2427193-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | Omeros Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129036-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |